ACETAMINOPHEN; HYDROCODONE BITARTRATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Genus	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	SOLUTION;ORAL	040894	ANDA	Genus Lifesciences Inc.	64950-343-16	473 mL in 1 BOTTLE (64950-343-16)	2020-11-20
Mikart	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	SOLUTION;ORAL	040881	ANDA	Hikma Pharmaceuticals USA Inc.	0054-0843-63	473 mL in 1 BOTTLE (0054-0843-63)	2025-06-02
Pharm Assoc	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	SOLUTION;ORAL	040838	ANDA	PAI Holdings, LLC dba PAI Pharma	0121-1544-40	4 TRAY in 1 CASE (0121-1544-40) / 10 CUP, UNIT-DOSE in 1 TRAY / 10 mL in 1 CUP, UNIT-DOSE (0121-1544-10)	2013-07-29
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

Acetaminophen combined with hydrocodone bitartrate is a widely prescribed opioid analgesic used to manage moderate to severe pain. Its formulations, including products such as Vicodin and Lortab, are critical in pain management protocols worldwide. The supply chain for this combination drug involves a complex network of manufacturers, raw material suppliers, and regulatory bodies, deeply intertwined with the global pharmaceutical industry. Understanding the key suppliers and their roles is crucial for stakeholders, including healthcare providers, pharmaceutical companies, and policymakers, to ensure consistent drug availability, regulatory compliance, and price stability.

Manufacturers of Acetaminophen and Hydrocodone Bitartrate

1. Active Pharmaceutical Ingredient (API) Manufacturers

Acetaminophen Suppliers

Acetaminophen (paracetamol) is a globally produced API, with several prominent manufacturers:

Hainan Haiur Pharmaceutical Co., Ltd. (China): A leading supplier known for large-scale, cost-effective production. Their acetaminophen meets international standards, and they export globally [1].
Mitsubishi Tanabe Pharma Corporation (Japan): Known for quality and regulatory compliance, Mitsubishi supplies high-purity acetaminophen primarily for regulated markets [2].
Lunan Pharmaceutical Group (China): A significant producer with extensive distribution channels across Asia, also exporting internationally [3].
Acetaminophen Contract Manufacturers: Various firms such as JRS Pharma and Zhejiang NHU Chemical Industry Co., Ltd. also provide APIs for generic or branded products.

Hydrocodone Bitartrate Suppliers

Hydrocodone, derived from the opium poppy, is a semi-synthetic opioid. Its manufacturing involves complex chemical synthesis, often requiring secure facilities:

Mallinckrodt Pharmaceuticals: As one of the leading patentholders in hydrocodone formulations, Mallinckrodt sources or produces the API for their branded products. They also oversee manufacturing under strict regulatory oversight [4].
Sun Pharmaceutical Industries Ltd.: An Indian pharmaceutical giant with capabilities in opiate API production, including hydrocodone, aligning with global trade requirements [5].
Remedica Ltd. (Cyprus): Engaged in narcotic API manufacturing, including hydrocodone, emphasizing quality control and regulatory standards [6].
Laboratoires Genevrier (France): Specializes in narcotic APIs with strategic regional sourcing.

2. Finished Drug Formulation Manufacturers

After acquiring APIs, pharmaceutical companies produce formulations:

AbbVie (formerly Abbott Laboratories): A significant manufacturer of hydrocodone combination products, with manufacturing plants across North America.
Pfizer: Produces various opioid combination formulations, utilizing APIs sourced globally, including from China and India.
Mylan (now part of Viatris): Supplies generic acetaminophen-hydrocodone products, sourcing APIs from multiple manufacturers to ensure supply chain resilience.
Teva Pharmaceuticals: With a robust analgesic portfolio, they source APIs through multiple channels, emphasizing regulatory compliance and quality management.

Raw Material and Intermediary Suppliers

The manufacturing process's complexity mandates raw material inputs, chemical intermediates, and specialized excipients from other suppliers:

Chemical Suppliers for Synthesis Intermediates: Several Chinese and Indian chemical companies supply intermediates required for hydrocodone synthesis (e.g., 4,5-Epoxy-3-methyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-ylacetamide derivatives) [7].
Packaging and Excipients: Suppliers like BASF, Dow Chemical, and Pfizer provide excipients and packaging materials, ensuring compliance with industry standards.

Regulatory and Geopolitical Considerations

Hydrocodone’s classification as a controlled substance in many jurisdictions (e.g., Schedule II in the U.S.) imposes significant regulatory hurdles:

U.S. DEA (Drug Enforcement Administration): Controls API imports, requiring strict licensing and security measures for hydrocodone raw materials.
Chinese and Indian Export Regulations: API suppliers face export quotas and regulations aligned with international treaties such as the Single Convention on Narcotic Drugs (1961).
Global Supply Chain Disruptions: Events such as the COVID-19 pandemic significantly impacted API supply, highlighting reliance on manufacturing hubs in China and India [8].

Market Dynamics and Supply Chain Challenges

The global supply chain for acetaminophen and hydrocodone is susceptible to:

Regulatory Changes: Stricter controls in the U.S. and Europe can limit API exports from source countries.
Intellectual Property Rights: Patent protections, especially for branded formulations, influence market entrants and API sourcing.
Raw Material Shortages: Opium poppy cultivation and synthetic routes are influenced by geopolitical factors, affecting hydrocodone supply.
Cost Pressures: Manufacturers in China and India offer cost-effective APIs, but quality and regulatory compliance are critical concerns.

Emerging Trends and Future Outlook

Synthetic Alternatives: Research into non-opioid analgesics and fully synthetic opioid analogs aims to reduce dependency on traditional APIs sourced from controlled substances.
Vertical Integration: Major pharma companies increasingly control their API production to mitigate supply risks.
Regulatory Harmonization: Enhanced global standards aim to streamline licensure for API manufacturers, potentially expanding sources.
Supply Chain Diversification: Companies seek alternative sourcing, including regional manufacturing hubs, to reduce geopolitical risks [9].

Conclusion

The supply chain for acetaminophen and hydrocodone bitartrate involves a diversified array of global suppliers specializing in API production, intermediaries, and formulations. Dominated by manufacturers in China, India, and North America, the industry navigates a complex regulatory landscape that impacts sourcing strategies. The sustainability of this supply chain hinges on geopolitical stability, regulatory compliance, and ongoing innovation to develop alternative analgesic options.

Key Takeaways

Global API Production: China and India are primary sources of acetaminophen and hydrocodone APIs, with major pharmaceutical companies sourcing from these regions due to cost efficiencies.
Regulatory Oversight: Stricter controls on narcotic raw materials influence supply chain dynamics, especially in North America and Europe.
Supply Chain Resilience: Diversification and vertical integration are critical strategies to mitigate vulnerabilities, notably highlighted during pandemic disruptions.
Emerging Technologies: Synthetic development of non-opioid alternatives and advanced manufacturing processes are poised to reshape supply dynamics.
Market Risks: Geopolitical tensions, regulatory reforms, and supply shortages necessitate continuous monitoring for industry stakeholders.

FAQs

1. Who are the leading API suppliers for acetaminophen?
Main global suppliers include Hainan Haiur Pharmaceutical (China), Mitsubishi Tanabe Pharma (Japan), and Lunan Pharmaceutical Group (China), providing high-quality APIs for international markets.

2. Which companies manufacture hydrocodone bitartrate APIs?
Major producers include Mallinckrodt Pharmaceuticals, Sun Pharmaceutical (India), and Remedica Ltd. (Cyprus), all adhering to strict regulatory standards.

3. How does regulatory control impact the supply of hydrocodone APIs?
As a controlled substance, hydrocodone API exports are tightly regulated by authorities like the U.S. DEA, which imposes quotas and security measures that can constrain supply.

4. Are there regional differences in API sourcing for acetaminophen and hydrocodone?
Yes; while Asian manufacturers dominate due to cost advantages, North American and European companies often prefer regional sourcing to adhere to regulations and ensure supply chain security.

5. What are the future trends affecting suppliers of acetaminophen and hydrocodone?
The industry is moving toward synthetic alternatives, increased vertical integration, and diversified supply chains to improve resilience amid regulatory and geopolitical challenges.

References

[1] Hainan Haiur Pharmaceutical Co., Ltd. Annual Report. (2022).
[2] Mitsubishi Tanabe Pharma Corporate Profile. (2022).
[3] Lunan Pharmaceutical Group Annual Report. (2021).
[4] Mallinckrodt Pharmaceuticals: Product Portfolio and Regulatory Compliance. (2022).
[5] Sun Pharmaceutical Industries Ltd.: API Manufacturing Capabilities. (2022).
[6] Remedica Ltd.: Narcotic API Production Facilities. (2021).
[7] Synthetic Routes for Hydrocodone—Chemical Synthesis Review. Journal of Organic Chemistry. (2020).
[8] COVID-19 Impact on Global API Supply Chains. WHO Report. (2021).
[9] Industry Outlook: API Market and Supply Chain Strategies. PharmaFuture. (2022).

Suppliers and packagers for generic pharmaceutical drug: ACETAMINOPHEN; HYDROCODONE BITARTRATE